Compounding Pharmacy Statistics 2026 (Peptide Data)

This article is compiled by the Phoenix Meds Inc. Team — A Healthcare Supply Coordination Platform with 20+ years in pharmaceutical distribution. Every statistic above links to its primary source. (Updated: July 2026)

Writers, researchers, and clinic operators keep asking us for the same numbers — market sizes, facility counts, inspection data, shortage figures. So we put them all on one page, with sources. Feel free to cite any statistic here; we’d appreciate a link back to this page as the compilation source.

The 503B Outsourcing Facility Landscape (FDA Registry Data)

Our team reviews FDA’s registered outsourcing facilities list, which the agency updates weekly. From the May 2026 update:

95 — outsourcing facilities registered with FDA under Section 503B nationwide. That’s the entire universe of facilities federally authorized to compound office-use stock in bulk. (New to the 503A/503B distinction? Start with our 503A vs 503B Complete Guide.) (FDA, registry updated 5/5/2026)
~4 in 10 — share of registered facilities listed as “not yet inspected” by FDA, by our count of the May 2026 registry. Many of these are recent registrants awaiting their first risk-based inspection — a reminder that “FDA-registered” and “FDA-inspected” are not the same claim. (Phoenix Meds analysis of FDA registry, May 2026)
At least 7 — warning letters FDA issued to registered 503B facilities between March 2025 and April 2026, per the actions column of the registry. (Phoenix Meds analysis of FDA registry, May 2026)
Texas and Florida lead the registry by facility count, by our tally of listed locations. (Phoenix Meds analysis of FDA registry, May 2026)

Note on our registry analysis: counts reflect the 5/5/2026 data-lock version of FDA’s table and will drift as the registry updates. We refresh this section quarterly.

Compounding Pharmacy Market Size

Market estimates differ by methodology, so we show named sources rather than one blended number:

$6.98 billion — U.S. compounding pharmacy market in 2025, projected to reach $12.79 billion by 2035 (6.24% CAGR). (Towards Healthcare, 2025)
$6.45 billion — U.S. compounding pharmacies market in 2025, on track for roughly $10.9–11.5 billion by 2034–2035. (Precedence Research, 2025)
$15.83 billion — global compounding pharmacy market in 2025, expected to reach $16.78 billion in 2026. (Mordor Intelligence)
$1.35 billion — projected U.S. 503B compounding pharmacies segment in 2026. (Towards Healthcare)

Peptide Therapeutics Market

Estimates for this market vary widely because firms define the segment differently (some include GLP-1 blockbusters, some don’t). The honest picture is a range:

$51.6 billion to $140.9 billion — the span of published 2025 global peptide therapeutics market estimates across major research firms (Research Nester at the low end; Grand View Research at the high end; Fortune Business Insights at $131.95 billion; Roots Analysis at $90.2 billion).
~$81–87 billion by 2034–2035 — convergent longer-range projections from several firms (Precedence Research, Towards Healthcare).
The driver everyone agrees on: peptide drugs — led by GLP-1 receptor agonists — moved from niche to mainstream, pulling clinical and research interest toward the broader peptide class. We’ve covered the clinic-level version of this shift in Lipovite vs GLP-1 weight loss injections and AOD 9604 vs tirzepatide.

Drug Shortages (Why Sourcing Resilience Matters)

223 — active drug shortages in the U.S. in Q1 2026, rising for a second consecutive quarter. (ASHP Drug Shortages Statistics, April 2026)
323 — the all-time high in active shortages, hit in Q1 2024. (ASHP)
Injectables are persistently overrepresented among shortages — the exact category clinics stock for in-office administration, and a core reason multi-supplier sourcing exists as a strategy (how our coordination model addresses it).
December 2024 / February 2025 — FDA declared the tirzepatide and semaglutide shortages resolved, respectively, ending the period when compounders could rely on shortage-based flexibilities for those GLP-1 drugs — a shift that reshaped compounding demand and enforcement attention. (FDA Drug Shortages Database)

The Regulatory Backdrop (Numbers Worth Remembering)

750+ infections, 60+ deaths, 20 states — the toll of the 2012 fungal meningitis outbreak traced to contaminated compounded injections from the New England Compounding Center. (FDA)
November 27, 2013 — enactment of the Drug Quality and Security Act (DQSA), which created the 503B outsourcing facility category in response. (FDA)
0 — the number of compounded drugs that are FDA-approved. FDA does not review any compounded drug for safety, effectiveness, or quality before it reaches patients — from a 503A or a 503B. Verification is the buyer’s job — our 503A vs 503B guide includes the 10-minute verification checklist. (FDA)
Weekly — how often FDA updates its registered outsourcing facilities table, making supplier verification a check anyone can run in minutes. (FDA)

If you use an individual statistic, please cite its primary source (listed with each stat) — and we appreciate a link to this compilation.

Sources

FDA — Registered Outsourcing Facilities (updated 5/5/2026)
FDA — Human Drug Compounding Laws
FDA — Drug Shortages Database (GLP-1 shortage resolutions)
ASHP — Drug Shortages Statistics (Q1 2026)
Towards Healthcare — U.S. Compounding Pharmacy Market; U.S. 503B Compounding Pharmacies Market (2025–2026)
Precedence Research — U.S. Compounding Pharmacies Market (2025)
Mordor Intelligence — Compounding Pharmacy Market (global)
Grand View Research; Fortune Business Insights; Roots Analysis; Research Nester — Peptide Therapeutics Market reports (2025)

Disclaimer:

Phoenix Meds Inc. is a healthcare supply coordination platform connecting licensed clinics with licensed 503A/503B pharmacies, wholesalers, and distributors. We do not sell, dispense, or manufacture medications.